| CTRI Number |
CTRI/2025/10/095963 [Registered on: 13/10/2025] Trial Registered Prospectively |
| Last Modified On: |
11/10/2025 |
| Post Graduate Thesis |
No |
| Type of Trial |
Observational |
|
Type of Study
|
Cohort Study |
| Study Design |
Other |
|
Public Title of Study
|
Comparison of 2 types of treatments, one given through blood route and other through lungs, for persistent seizures using blood tests |
|
Scientific Title of Study
|
Changes in neuronal cellular injury and neural inflammation during refractory status epilepticus (RSE) treatment with Isoflurane and Midazolam – a biomarker-based study |
| Trial Acronym |
NIL |
|
Secondary IDs if Any
|
| Secondary ID |
Identifier |
| NIL |
NIL |
|
|
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
|
| Name |
DR SONIA BANSAL |
| Designation |
Additional Professor |
| Affiliation |
NIMHANS |
| Address |
Department of Neuroanaesthesia and Neurocritical Care, 3rd floor, Faculty Block, Neurocentre, NIMHANS (near Bangalore Milk Dairy), Bengaluru
Bangalore KARNATAKA 560029 India |
| Phone |
9008721921 |
| Fax |
|
| Email |
itz.sonia77@gmail.com |
|
Details of Contact Person Scientific Query
|
| Name |
DR SONIA BANSAL |
| Designation |
Additional Professor |
| Affiliation |
NIMHANS |
| Address |
Department of Neuroanaesthesia and Neurocritical Care, 3rd floor, Faculty Block, Neurocentre, NIMHANS (near Bangalore Milk Dairy), Bengaluru
Bangalore KARNATAKA 560029 India |
| Phone |
9008721921 |
| Fax |
|
| Email |
itz.sonia77@gmail.com |
|
Details of Contact Person Public Query
|
| Name |
DR SONIA BANSAL |
| Designation |
Additional Professor |
| Affiliation |
NIMHANS |
| Address |
Department of Neuroanaesthesia and Neurocritical Care, 3rd floor, Faculty Block, Neurocentre, NIMHANS (near Bangalore Milk Dairy), Bengaluru
Bangalore KARNATAKA 560029 India |
| Phone |
9008721921 |
| Fax |
|
| Email |
itz.sonia77@gmail.com |
|
|
Source of Monetary or Material Support
|
| Indian Society of Critical Care Medicine |
|
|
Primary Sponsor
|
| Name |
Indian Society of Critical Care Medicine |
| Address |
Unit 13 and 14 First floor Hind Service Industries Premises Co operative Society Near Chaitya Bhoomi, Off Veer Savarkar Marg Dadar Mumbai400028 |
| Type of Sponsor |
Other [Private Organisation] |
|
|
Details of Secondary Sponsor
|
|
|
Countries of Recruitment
|
India |
|
Sites of Study
|
| No of Sites = 1 |
| Name of Principal
Investigator |
Name of Site |
Site Address |
Phone/Fax/Email |
| DR SONIA BANSAL |
NIMHANS |
Department of Neuroanaesthesia and Neurocritical Care, 3rd floor, Faculty block, Neurocentre Bangalore KARNATAKA |
09008721921
itz.sonia77@gmail.com |
|
|
Details of Ethics Committee
|
| No of Ethics Committees= 1 |
| Name of Committee |
Approval Status |
| Institute Ethics Committee (BS and NS) |
Approved |
|
|
Regulatory Clearance Status from DCGI
|
|
|
Health Condition / Problems Studied
|
| Health Type |
Condition |
| Patients |
(1) ICD-10 Condition: G409||Epilepsy, unspecified, |
|
|
Intervention / Comparator Agent
|
| Type |
Name |
Details |
| Intervention |
Nil |
Nil |
| Intervention |
Nil |
Nil |
| Intervention |
Nil |
Nil |
| Intervention |
Nil |
Nil |
|
|
Inclusion Criteria
|
| Age From |
18.00 Year(s) |
| Age To |
80.00 Year(s) |
| Gender |
Both |
| Details |
Patients with refractory status epilepticus unresponsive to first line and two second line intravenous antiepileptics and requiring anesthetic medications to control seizures |
|
| ExclusionCriteria |
| Details |
1.Known, suspected history of malignant hyperthermia
2.Patients with severe acute respiratory distress syndrome and arterial oxygen tension to inspired oxygen concentration ratio less than 100 requiring inverse ratio ventilation or prone ventilation
3.Patients with diagnosis of Mitochondrial disease
|
|
|
Method of Generating Random Sequence
|
Not Applicable |
|
Method of Concealment
|
Not Applicable |
|
Blinding/Masking
|
Not Applicable |
|
Primary Outcome
|
| Outcome |
TimePoints |
| Compare the levels of serum NSE and IL-10 between patients receiving isoflurane and midazolam for treatment of RSE |
At baseline before starting the drug and after stopping the drug (isoflurane or midazolam) |
|
|
Secondary Outcome
|
| Outcome |
TimePoints |
| In hospital mortality & Glasgow outcome scale extended |
At discharge & 6 months after discharge |
|
|
Target Sample Size
|
Total Sample Size="40" Sample Size from India="40"
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" |
|
Phase of Trial
|
N/A |
|
Date of First Enrollment (India)
|
15/11/2025 |
| Date of Study Completion (India) |
Applicable only for Completed/Terminated trials |
| Date of First Enrollment (Global) |
Date Missing |
| Date of Study Completion (Global) |
Applicable only for Completed/Terminated trials |
|
Estimated Duration of Trial
|
Years="3" Months="0" Days="0" |
|
Recruitment Status of Trial (Global)
|
Not Yet Recruiting |
| Recruitment Status of Trial (India) |
Not Yet Recruiting |
|
Publication Details
|
N/A |
|
Individual Participant Data (IPD) Sharing Statement
|
Will individual participant data (IPD) be shared publicly (including data dictionaries)?
Response - NO
|
|
Brief Summary
|
After admission to NCCU if patient is not intubated in the emergency department it will be done in the NCCU and patient will be ventilated Vitals will be monitored every 15 min Patient will continue to receive the prescribed AEDs All patients will undergo complete hematology, biochemistry electrocardiography and neurological work-up in the form of computed tomography or Magnetic resonance Imaging scan cerebrospinal fluid examination if indicated toxicology screening and AED drug levels for patients on AEDs If the seizures are not controlled with the initial benzodiazepine and two AEDs the patient will be diagnosed to have RSE and becomes eligible for the study Bispectral Index monitoring will be performed and wherever feasible cerebral oxygen saturation monitoring will also be done The patients will receive either midazolam or isoflurane for the treatment of RSE We plan to recruit alternate patient into midazolam and isoflurane group In the midazolam group midazolam will be administered as a bolus of 0.05 mg per kg followed by initiation of infusion at 0.1mg per kg per hr. If the seizures recur more than three times in 15 min or the seizures are uncontrolled for 15 min then the dose will be escalated by 0.1 mg per kg per hr The dose at which seizures are controlled will be noted This escalation will continue if seizures are not terminated till a maximum dose of 0.4 mg per kg per h after which the RSE will be considered Super RSE and treatment failure of the study drug will be considered Thereafter thiopentone infusion will be initiated with a bolus of 3 mg per kg followed by a continuous infusion at a rate of 3 to 5 mg per kg per hr In the isoflurane group isoflurane will be administered using anaesthesia machine and a dedicated vaporiser using a low flow technique and carbondioxide absorber circle system Isoflurane will be administrated at 0.6 MAC. If the seizures recur more than three times in 15 min, or the seizures are uncontrolled for 15 min then the dose will be escalated by 0.2 MAC This escalation will continue if seizures are not terminated till a maximum dose of 1.2 MAC The MAC at which seizures are controlled will be noted If seizures are not controlled even at 1.2 MAC RSE will be considered SRSE, and treatment failure of the study drug will be considered Thereafter thiopentone infusion will be initiated with a bolus of 3 mg per kg followed by a continuous infusion at a rate of 3 to 5 mg per kg per hr The dose at which seizures are controlled will be noted If seizures are controlled with isoflurane or midazolam, the particular dose of the drug will be continued for 48 hours after which the dose will be reduced by 20 percent every 12 hours and eventually stopped. At any stage of drug tapering if the seizures recur then tapering will be halted and the dose increased to the previous level and continued for another 24 h Tapering will be restarted if there is no seizure during this 24 h period NSE and IL-10 levels Blood samples for estimation of NSE and IL10 levels will be collected before starting the respective study drug and immediately after stopping the drug. A 2ml blood sample will be collected at each time point, the serum will be separated and stored Estimation of NSE and IL10 levels will be done using ELISA technique using commercially available kits as per the manufacturer instructions |